Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

NCT02726997 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02726997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02726997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 6, 2016
Completion date
December 31, 2027
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii fallopian tube cancer ajcc v7, stage iii ovarian cancer ajcc v6 and v7, stage iii primary peritoneal cancer ajcc v7, stage iiia fallopian tube cancer ajcc v7, stage iiia ovarian cancer ajcc v6 and v7, stage iiia primary peritoneal cancer ajcc v7, stage iiib fallopian tube cancer ajcc v7, stage iiib ovarian cancer ajcc v6 and v7, stage iiib primary peritoneal cancer ajcc v7, stage iiic fallopian tube cancer ajcc v7, stage iiic ovarian cancer ajcc v6 and v7, stage iiic primary peritoneal cancer ajcc v7, stage iv fallopian tube cancer ajcc v6 and v7, stage iv ovarian cancer ajcc v6 and v7, stage iv primary peritoneal cancer ajcc v7